Colonis Pharma Strengthens Longstanding Partnership with Adragos Pharma, Athens

colonis and adragos logos

Colonis Pharma Strengthens Longstanding Partnership with Adragos Pharma, Athens

Colonis Pharma, a leading pharmaceutical company focused on innovative value-added medicines, has announced the strengthening of its longstanding partnership with Adragos Athens (formerly known as Lamda Laboratories SA), a specialist in pharmaceutical product development and supply. This move solidifies Colonis Pharma’s commitment to advancing its value-added medicines development portfolio and ensuring the security of its supply chain.

Colonis Pharma has a rich history of collaboration with Lamda Laboratories, spanning over a decade. Together, Colonis and Lamda Laboratories have worked on formulation development for value-added medicines, fostering innovation and delivering high-quality products to patients.

The extension of this partnership brings significant benefits to Colonis Pharma. Adragos Athens’ expertise in the development of new formulations enhances Colonis Pharma’s capabilities in expanding its portfolio of value-added medicines. By leveraging the latest technologies and adhering to the highest standards, Adragos Athens ensures the quality and reliability of Colonis Pharma’s products.

Andy Trouton, Managing Director of Colonis Pharma, expressed his enthusiasm for the extended partnership, stating,

“Since the inception of Colonis, we have been working closely with Lamda Laboratories, now Adragos Athens, as our product development partner. I’m delighted we have now extended this relationship further by entering into this long-term supply agreement, which will strengthen our supply chain and ensure continuity for the many patients who benefit from our medicines.”

Angelos Karatzas, Managing Director of Adragos Athens, commented on the extension of this partnership,

“Through the long journey of our collaboration, as well as developing value-added medicines to meet patients’ needs, Adragos Athens has upgraded its facilities, extending its capabilities to enable the future development and supply of high potent drugs.”

The new agreement between Colonis Pharma and Adragos Athens is a long-term development and supply agreement aimed at strengthening the supply chain and ensuring a seamless continuity of supply.  By leveraging Adragos Athens’ extensive capabilities in supply chain management, Colonis Pharma can enhance operational efficiency and maintain an uninterrupted flow of its value-added medicines to the patients who benefit from them.

GB-CPL-0-081
February 2024

Stay up to date, connect with us on Social Media

You are now leaving

You are now leaving the Colonis website and being redirected to a Clinigen Group website.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the Clinigen website.

You are now leaving

You are now leaving the Colonis website and being redirected to a Clinigen Group website.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the Clinigen website.

You are now leaving

You are now leaving the Colonis website and being redirected to a Clinigen Group website.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the Clinigen website.

You are now leaving

You are now leaving the Colonis website and being directed to an external website for which Colonis is not responsible.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the external website.

You are now leaving

You are now leaving the Colonis website and being directed to an external website for which Colonis is not responsible.

Click “Cancel” to remain on the Colonis website.
Click “Continue” to visit the external website.